Zentalis Pharmaceuticals, Inc. (ZNTL) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Core Viewpoint - Zentalis Pharmaceuticals, Inc. is under investigation due to a partial clinical hold placed by the FDA on its studies involving azenosertib, which has led to a decline in its stock price [2]. Investigation Details - On June 18, 2024, Zentalis announced that the FDA had placed a partial clinical hold on three studies: the Phase 1 ZN-c3-001 dose-escalation study in solid tumors, the Phase 2 ZN-c3-005 (DENALI) study in platinum-resistant ovarian cancer, and the Phase 2 ZN-c3-004 (TETON) study in uterine serous carcinoma [2]. Next Steps - Investors who have information related to the investigation or who purchased Zentalis securities are encouraged to assist by visiting the law firm's website or contacting their representatives [3]. Legal Representation - Bronstein, Gewirtz & Grossman, LLC operates on a contingency fee basis, meaning they will only seek reimbursement for expenses and attorney fees if they are successful in the case [4]. Firm Background - Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm specializing in representing investors in securities fraud class actions and has recovered hundreds of millions of dollars for investors across the nation [5].